Endometriosis: seeking optimal management in women approaching menopause


To link to this article: https://doi.org/10.1080/13697137.2018.1549213

Published online: 10 Jan 2019.

Article views: 160

View Crossmark data
Endometriosis: seeking optimal management in women approaching menopause

L. Alio\textsuperscript{a}, S. Angioni\textsuperscript{b}, S. Arena\textsuperscript{c}, L. Bardiromo\textsuperscript{d}, V. Bergamini\textsuperscript{e}, N. Berlanda\textsuperscript{f}, V. Bonanni\textsuperscript{h}, C. Bonin\textsuperscript{e}, L. Buggio\textsuperscript{g}, M. Candiand\textsuperscript{i}, G. Centinie\textsuperscript{i}, M. N. D’Alteriolo\textsuperscript{j}, F. De Stefano\textsuperscript{a}, A. Di Cello\textsuperscript{c}, C. Exacoustos\textsuperscript{k}, L. Fedele\textsuperscript{g}, M. P. Frattarulo\textsuperscript{g}, E. Geraci\textsuperscript{b}, E. Lavarini\textsuperscript{i}, L. Lazzeri\textsuperscript{i}, S. Luissi\textsuperscript{i}, A. Maiorana\textsuperscript{m}, S. Makieva\textsuperscript{m}, F. Maneschi\textsuperscript{i}, F. Martire\textsuperscript{k}, C. Massarotti\textsuperscript{b,p}, A. Mattei\textsuperscript{l}, L. Muzzi\textsuperscript{b}, J. Ottolin\textsuperscript{d}, L. Pagliardini\textsuperscript{m}, A. Perandine\textsuperscript{i}, F. Perelli\textsuperscript{l}, I. Pino\textsuperscript{b}, M. G. Porpora\textsuperscript{b}, V. Remorgida\textsuperscript{b,p}, G. Scagnelli\textsuperscript{s}, R. Seracchioli\textsuperscript{b}, E. Solima\textsuperscript{e}, E. Somigliana\textsuperscript{g}, G. Sorrenti\textsuperscript{k}, A. Ticino\textsuperscript{h}, R. Venturella\textsuperscript{p}, P. Vigan\textsuperscript{m}\textsuperscript{m}, M. Vignali\textsuperscript{f}, F. Zullo\textsuperscript{u} and E. Zupi\textsuperscript{k}

\textsuperscript{a}Department of Obstetrics and Gynecology, Civico Hospital, Palermo, Italy; \textsuperscript{b}Department of Surgical Sciences, University of Cagliari, Cagliari, Italy; \textsuperscript{c}Department of Obstetrics and Gynecology, Azienda Ospedaliera Perugia, Perugia, Italy; \textsuperscript{d}Gynecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy; \textsuperscript{e}Department of Obstetrics and Gynecology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; \textsuperscript{f}Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; \textsuperscript{g}Gynaecology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; \textsuperscript{h}Department of Gynecology, Obstetrics and Urology, Sapienza University of Rome, Rome, Italy; \textsuperscript{i}Department of Molecular and Developmental Medicine, Obstetrics and Gynecology, University of Siena, Siena, Italy; \textsuperscript{j}Department of Clinical and Experimental Medicine, Obstetrics and Gynecology, Università degli Studi Magna Graecia, Catanzaro, Italy; \textsuperscript{k}Department of Biomedicine and Prevention, Università degli studi di Roma ‘Tor Vergata’, Rome, Italy; \textsuperscript{l}Department of Obstetrics and Gynecology, Asola Hospital, Mantova, Italy; \textsuperscript{m}Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy; \textsuperscript{n}Department of Obstetrics and Gynecology, Università degli Studi di Milano, Milan, Italy; \textsuperscript{o}Academic Unit of Obstetrics and Gynaecology, Ospedale Policlinico San Martino, Genoa, Italy; \textsuperscript{p}Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, Genoa, Italy; \textsuperscript{q}Department of Minimally Invasive Gynaecological Surgery, Centre Tuscany USL, Florence, Italy; \textsuperscript{r}Department of Experimental, Clinical and Biomedical Sciences, Obstetrics and Gynaecology, University of Florence, Florence, Italy; \textsuperscript{s}Department of Obstetrics and Gynecology, University of Milan, Macedonio Melloni Hospital, Milan, Italy; \textsuperscript{t}Gynecology and Physiopathology of Human Reproductive Unit, University of Bologna, S. Orsola-Malpighi Hospital of Bologna, Bologna, Italy; \textsuperscript{u}Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy

ABSTRACT
The incidence of endometriosis in middle-aged women is not minimal compared to that in the reproductive age group. The treatment of affected women after childbearing age to the natural transition toward menopause has received considerably poor attention. Disease management is problematic for these women due to increased contraindications regarding hormonal treatment and the possibility for malignant transformation, considering the increased cancer risk in patients with a long-standing history of the disease. This state-of-the-art review aims for the first time to assess the benefits of the available therapies to help guide treatment decisions for the care of endometriosis in women approaching menopause. Progestins are proven effective in reducing pain and should be preferred in these women due to increased contraindications. According to the international guidelines that lack precise recommendations, hysterectomy with bilateral salpingo-ooophorectomy should be the definitive therapy in women who have completed their reproductive arc, if medical therapy has failed. Strict surveillance or surgery with removal of affected gonads should be considered in cases of long-standing or recurrent endometriomas, especially in the presence of modifications of ultrasonographic cyst patterns. Although rare, malignant transformation of various tissues in endometriosis patients has been described, and management is herein discussed.

ARTICLE HISTORY
Received 17 May 2018
Revised 29 October 2018
Accepted 2 November 2018
Published online 11 January 2019

KEYWORDS
Perimenopause; endometriosis; middle-aged women; management; endometriosis treatment; endometriosis malignant transformation

Introduction
Endometriosis has traditionally been considered a disease of the reproductive years. The prevalence of the disease seems to be \( \approx \) 5%, with a peak between 25 and 35 years of age.\textsuperscript{1} As an estrogen-dependent disease, it tends to undergo regression after menopause. Indeed, Punnonen \textit{et al.}\textsuperscript{2} describe a frequency of 2.2% for postmenopausal endometriosis. Current literature on endometriosis addresses justifiably specific management concerns of reproductive age women, including infertility and pelvic pain. Data on postmenopausal disease, although more limited and largely confined to case reports and retrospective studies, have some space in the current literature. Conversely, there has so far been a notable lack of interest for the treatment options of affected women after childbearing age to the natural transition toward menopause.
According to an estimation of the Icelandic population between 1981 and 2000, using Iceland’s extensive record linkage systems in which each case of visually diagnosed and histologically verified endometriosis was cross-checked against the nationwide pathology registry, age-specific incidence in the age groups 30–34, 35–39, and 40–44 years was estimated at 13.4, 13.3, and 13.2/10,000 person-years, respectively. For the age group 45–49 years it was only slightly lower, being around 12/10,000 person-years during the latter half of the study period (1991–2000). In a retrospective German epidemiological study, a descriptive analysis of 42,079 women undergoing surgical treatment due to histologically confirmed endometriosis in the period 2005–2006 was carried out. The premenopausal group (age 0–45 years) was represented by 80.36% of the patients, while 7191 patients (17.09%) belonged to the perimenopausal group (age 45–55 years). A total of 16,969 patients (40.33%) admitted to hospital and treated for endometriosis were over the age of 40 years.

Thus, although the incidence of endometriosis appears high in perimenopause, surprisingly the interest toward this category of affected women has been marginal. The topic was addressed for the first time in 1993 by Witt and Barad with a review aimed at discussing the management of endometriosis in women older than 40 years, with a distinct focus on women still requiring childbearing and on menopausal women. No other contribution can be appreciated in the literature. However, women in the transitional time between reproductive life and menopause represent a population facing unaccustomed issues while treating disease-associated pain symptoms and preventing recurrences. Some of these include the increased risk of medical contraindications to combined hormonal contraceptive (COC) use and the risk of malignant transformation of the disease considering that the cancer risk markedly increases in women who have a long-standing history of the disease.

On these bases, the aim of this state-of-the-art review is to gain insight into the benefits and safety of the various therapies for endometriosis that can help guide treatment decisions for the care of women approaching menopause.

<table>
<thead>
<tr>
<th>Onset of natural menopause in endometriosis</th>
</tr>
</thead>
</table>
| Few data are available regarding the age at menopause of women with endometriosis. The majority of evidence argues that surgical treatment of ovarian endometriomas impairs ovarian reserve, hence earlier occurrence of menopause in affected women must be considered. Coccia et al. conducted a longitudinal prospective cohort study to investigate the age of menopause in patients who underwent surgery for endometriosis. Unfortunately, out of the 302 evaluated patients the mean age of menopause was only recorded for 43 women, which should not be considered a representative number. Additionally, a high percentage of women with premature ovarian failure (16.3%) was observed, the majority of whom were submitted to ovarian cystectomy for bilateral endometriomas. This underlies the need for a well-designed study addressing menopausal age in endometriosis, presently absent in the literature. It is not clear whether endometriosis per se can influence the onset of menopause. Ovarian endometriomas may contain many potentially toxic agents that may diffuse through the cyst wall and impact the ovarian reserve.

Other factors could interfere with the age at menopause of endometriosis women. A reduced body mass index has been associated with an early age at menopause, probably in relation to reduced estrogen production by the adipose tissue. A lower body weight is considered a risk factor for endometriosis as well. The international guidelines on endometriosis have not proposed precise recommendations for treatment of women approaching menopause, probably due to the lack of evidence collected from middle-aged women excluding those known to have previously undergone a natural or iatrogenic menopause.

Recommendations from the international guidelines on endometriosis
The international guidelines on endometriosis have not presented recommendations for treatment of women approaching menopause.
Table 2. Cases of acute bowel obstruction due to endometriosis in middle-aged women: literature review.

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Number of patients</th>
<th>Age (years)</th>
<th>Location</th>
<th>Symptoms</th>
<th>Type of endometriosis</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collins, 1957</td>
<td>2</td>
<td>(1) 40</td>
<td>Ileum and ileocecal valve</td>
<td>Colicky abdominal pain, vomiting</td>
<td>SBE + PE</td>
<td>Ileum resection and ileocecal anastomosis + appendectomy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2) 48</td>
<td>Sigmoid</td>
<td>Lower abdominal colicky pain, constipation, diarrhea</td>
<td>LBE + PE + PHE</td>
<td>Sigmoid resection and colorectal anastomosis + appendectomy + TAH (years before)</td>
</tr>
<tr>
<td>Scalvini, 1959</td>
<td>1</td>
<td>47</td>
<td>Ileum</td>
<td>Intermittent abdominal pain, biliary vomiting, abdominal distension</td>
<td>SBE</td>
<td>Ileal resection and end-to-end anastomosis</td>
</tr>
<tr>
<td>Midorikawa et al., 1997</td>
<td>1</td>
<td>42</td>
<td>Rectum</td>
<td>Lower abdominal pain</td>
<td>LBE + PE</td>
<td>Low anterior resection and TAH</td>
</tr>
<tr>
<td>Fujimoto et al., 2001</td>
<td>1</td>
<td>46</td>
<td>Ileocecal junction</td>
<td>Nausea, vomiting, abdominal distension</td>
<td>OE + PE + SBE</td>
<td>GnRH-a for 3 months</td>
</tr>
<tr>
<td>Almondolara et al., 2001</td>
<td>1</td>
<td>45</td>
<td>Sigmoid</td>
<td>Abdominal pain</td>
<td>LBE + PE</td>
<td>Anterior resection and colorectal anastomosis + myomectomy</td>
</tr>
<tr>
<td>Musa et al., 2001</td>
<td>1</td>
<td>42</td>
<td>Ileum</td>
<td>Diarrhea, bloating and abdominal pain protein-losing enteropathy, anasarca</td>
<td>SBE</td>
<td>Ileum resection + appendicectomy</td>
</tr>
<tr>
<td>Kupersmith et al., 2001</td>
<td>1</td>
<td>42</td>
<td>Sigmoid (fecal peritonitis secondary to a perforated cecum)</td>
<td>Abdominal pain, cramps, anorexia</td>
<td>LBE + PHE + OE + PE</td>
<td>Anterior resection and temporary colostomy</td>
</tr>
<tr>
<td>Varras et al., 2002</td>
<td>1</td>
<td>43</td>
<td>Sigmoid</td>
<td>Abdominal pain, symptoms of bowel occlusion</td>
<td>LBE + PE</td>
<td>Resection of descending and sigmoid colon + left oophorectomy</td>
</tr>
<tr>
<td>Sheikh et al., 2005</td>
<td>1</td>
<td>42</td>
<td>Ileocecal junction</td>
<td>Abdominal pain, diarrhea alternating with constipation, vomiting, poor appetite</td>
<td>SBE</td>
<td>Ileoceleocolic resection</td>
</tr>
<tr>
<td>Yildirim et al., 2005</td>
<td>1</td>
<td>46</td>
<td>Rectosigmoid junction</td>
<td>Vomiting and colicky abdominal pain</td>
<td>LBE</td>
<td>Low anterior rectal resection + temporary colostomy</td>
</tr>
<tr>
<td>De Ceglie et al., 2008</td>
<td>1</td>
<td>44</td>
<td>Distal ileum</td>
<td>Abdominal pain, diarrhea alternating with constipation</td>
<td>SBE/LBE</td>
<td>Right hemicolecotomy</td>
</tr>
<tr>
<td>Moutre de Alvim Andrade et al., 2008</td>
<td>2(1)</td>
<td>40</td>
<td>Rectum</td>
<td>Abdominal pain</td>
<td>LBE + PE</td>
<td>Rectosigmoidectomy + colostomy</td>
</tr>
<tr>
<td>Ruiz et al., 2008</td>
<td>1</td>
<td>41</td>
<td>Ileocecal valve</td>
<td>Cramping abdominal pain, diarrhea alternating with constipation, vomiting</td>
<td>SBE</td>
<td>Ileal resection + ileocolic anastomosis</td>
</tr>
<tr>
<td>de Jong et al., 2009</td>
<td>5(1)</td>
<td>43</td>
<td>Ileum</td>
<td>Nausea, vomiting, generalized abdominal pain and/or distention</td>
<td>SBE + PE</td>
<td>GnRH-a</td>
</tr>
<tr>
<td>Caselli et al., 2011</td>
<td>1</td>
<td>44</td>
<td>Sigmoid colon and the rectosigmoid junction</td>
<td>Hypogastric pain, abdominal cramps</td>
<td>LBE + OE + PE</td>
<td>Laparotomy: - Colostoma - Bilateral ureter stents</td>
</tr>
<tr>
<td>Unalp et al., 2012</td>
<td>1</td>
<td>45</td>
<td>Ileocecal valve</td>
<td>Abdominal pain, nausea, vomiting</td>
<td>SBE</td>
<td>Unknown</td>
</tr>
<tr>
<td>Khwaja et al., 2012</td>
<td>1</td>
<td>44</td>
<td>Terminal ileum</td>
<td>Colicky central abdominal pain, bilious vomiting, diarrhea</td>
<td>LBE</td>
<td>Right hemicolecotomy</td>
</tr>
<tr>
<td>Soylu et al., 2012</td>
<td>2</td>
<td>(1) 42</td>
<td>Cecum and sigmoid</td>
<td>Abdominal pain, nausea</td>
<td>LBE + PHE</td>
<td>Right hemicolecotomy</td>
</tr>
<tr>
<td>Lanitis et al., 2013</td>
<td>1</td>
<td>40</td>
<td>Rectosigmoid junction</td>
<td>Abdominal pain, constipation, bilious vomiting</td>
<td>LBE + PHE</td>
<td>Right hemicolecotomy</td>
</tr>
<tr>
<td>Azizad-Pinto and Clarke, 2014</td>
<td>1</td>
<td>48</td>
<td>Right-sided catamenial pneumothorax</td>
<td>Non-thoracic symptoms</td>
<td>LBE + catamenial pneumothorax</td>
<td>Rectosigmoidectomy, appendectomy, diverting loop ileostomy, TAH + BSO</td>
</tr>
<tr>
<td>Distal sigmoid colon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arafat et al., 2016</td>
<td>1</td>
<td>50</td>
<td>Rectosigmoid junction</td>
<td>Abdominal symptoms: left-sided abdominal pain; non-bloody, non-bilious emesis; alternating diarrhea, constipation</td>
<td>LBE + PHE</td>
<td>Sigmoidectomy and colostomy + TAH + BSO</td>
</tr>
<tr>
<td>López Carrasco et al., 2017</td>
<td>2</td>
<td>(1) 41</td>
<td>Rectosigmoid junction</td>
<td>Chronic pelvic pain, pseudo-obstruction symptoms</td>
<td>LBE + OE + PHE</td>
<td>Ileum and rectosigmoid resection + TAH + BSO, partial colpectomy</td>
</tr>
<tr>
<td>Chan et al., 2017</td>
<td>1</td>
<td>46</td>
<td>Distal ileum</td>
<td>Catamenial pseudo-obstruction</td>
<td>SBE + OE + PE</td>
<td>Ileum resection + right adnexectomy, myomectomy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Small bowel resection + end-to-end anastomosis</td>
</tr>
</tbody>
</table>

BSO, bilateral salpingo-oophorectomy; LBE, large-bowel endometriosis; OE, ovarian endometriosis; PE, pelvic endometriosis; PHE, previous endometriosis history; SBE, small-bowel endometriosis; TAH, total abdominal hysterectomy.
**Table 3. Clinical characteristics of endometriosis of the central and peripheral nervous system in middle-aged women: literature review.**

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Number of patients</th>
<th>Age (years)</th>
<th>Location</th>
<th>Symptoms</th>
<th>Type of endometriosis</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richards et al., 1991</td>
<td>1</td>
<td>46</td>
<td>Sciatic nerve</td>
<td>W, Sl</td>
<td>Extra</td>
<td>Surgery, danazol</td>
</tr>
<tr>
<td>Zager et al., 1998</td>
<td>1</td>
<td>45</td>
<td>Sciatic nerve</td>
<td>P, W, Sl</td>
<td>Intra-extra</td>
<td>Surgery (biopsy and external neurolysis), GnRH-a, TAH BSO</td>
</tr>
<tr>
<td>Vilos et al., 2002</td>
<td>3</td>
<td>41, 41, 40</td>
<td>Peritoneal endometriosis (n = 2), pelvic peritoneal pocket (n = 1)</td>
<td>P</td>
<td>Extra</td>
<td>Laparoscopic excision</td>
</tr>
<tr>
<td>Lacroix-Triki et al., 2004</td>
<td>1</td>
<td>50</td>
<td>Sciatic nerve</td>
<td>P, W</td>
<td>Intra-extra</td>
<td>TAH BSO, excision of pelvic endometriotic pockets, CT, GnRH-a, palliative RT</td>
</tr>
<tr>
<td>Fatemi et al., 2005</td>
<td>1</td>
<td>55</td>
<td>Lumbosacral plexus</td>
<td>P</td>
<td>Intra-extra</td>
<td>Aromatase inhibitors</td>
</tr>
<tr>
<td>Nagra et al., 2006</td>
<td>1</td>
<td>45</td>
<td>LS–S1 spinal nerves</td>
<td>P</td>
<td>Not reported</td>
<td></td>
</tr>
<tr>
<td>Floyd et al., 2011</td>
<td>1</td>
<td>44</td>
<td>Sciatic nerve, gluteal nerve</td>
<td>P, W, Sl</td>
<td>Intra-extra</td>
<td>Neurolysis, GnRH-a</td>
</tr>
<tr>
<td>Ceccon et al., 2011</td>
<td>1</td>
<td>41</td>
<td>Sacral plexus, pudendal nerve, sciatic nerve</td>
<td>P, W, Sl</td>
<td>Extrac</td>
<td>Neurolysis</td>
</tr>
<tr>
<td>Ghezzi et al., 2013</td>
<td>1</td>
<td>45</td>
<td>Sciatic nerve</td>
<td>P, W, Sl</td>
<td>Intra</td>
<td>Hormonal treatment</td>
</tr>
<tr>
<td>Vilela et al., 2015</td>
<td>1</td>
<td>49</td>
<td>Sciatic nerve, LS–S1 spinal nerves</td>
<td>P, W, Sl</td>
<td>Intra-extra</td>
<td>Hormonal treatment</td>
</tr>
<tr>
<td>Capek et al., 2016</td>
<td>1</td>
<td>45</td>
<td>Sciatic nerve</td>
<td>P, W, Sl</td>
<td>Intra-extra</td>
<td>TAH BSO, neurolysis</td>
</tr>
<tr>
<td>Aranyi et al., 2016</td>
<td>2</td>
<td>50, 46</td>
<td>Sciatic nerve (n = 2)</td>
<td>P, Sl (n = 1); P, W, Sl (n = 1)</td>
<td>Intra-extra (n = 2)</td>
<td>GnRH-a (n = 1), not available (n = 1)</td>
</tr>
<tr>
<td>Sarma et al., 2004</td>
<td>1</td>
<td>40</td>
<td>Cerebellar vermis</td>
<td>Gait disturbance, headache</td>
<td>Not available</td>
<td>Surgical excision</td>
</tr>
<tr>
<td>Agrawal et al., 2006</td>
<td>1</td>
<td>40</td>
<td>Conus medullaris</td>
<td>P, W, Sl</td>
<td>Intra</td>
<td>D12–L2 laminectomy danazol, BSO</td>
</tr>
</tbody>
</table>

BSO, bilateral salpingo-oophorectomy; CT, chemotherapy; GnRH-a, gonadotropin-releasing hormone agonist; P, pain; RT, radiotherapy; SL, sensory loss; TAH, total abdominal hysterectomy; W, weakness.

Intra, intraneural endometriosis (i.e. confined to the nerve); intra-extra, intraneural-extra-neural endometriosis (i.e. infiltrating the nerve as well as extending outside the nerve); extra, extra-neural endometriosis (i.e. outside the nerve, described as extrinsically 'compressing' or being 'attached' to the nerve).
Table 4. Cases of malignant transformation of bladder/neurological/thoracic endometriosis in middle-aged women: literature review.

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Number of patients</th>
<th>Age (years)</th>
<th>Type of endometriosis</th>
<th>Location and histological type of tumor</th>
<th>Symptoms and previous HoE</th>
<th>Management and recurrence</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balat et al., 1996</td>
<td>1</td>
<td>74</td>
<td>14</td>
<td>BE</td>
<td>Bladder clear cell adenocarcinoma invading rectum</td>
<td>Low back pain, proctorrhagia</td>
<td>MRI/TC</td>
</tr>
<tr>
<td>Mann et al., 2012</td>
<td>1</td>
<td>54</td>
<td>4</td>
<td>BE</td>
<td>Bladder endometrioid adenocarcinoma</td>
<td>Gross hematuria, irregular menses</td>
<td>Pelvic US</td>
</tr>
<tr>
<td>Tarumi et al., 2015</td>
<td>1</td>
<td>45</td>
<td>1</td>
<td>BE</td>
<td>Bladder endometrioid carcinoma</td>
<td>Urinary incontinence, Menorrhagia</td>
<td>Pelvic US, colonoscopy</td>
</tr>
<tr>
<td>Miller et al., 2016</td>
<td>1</td>
<td>44</td>
<td>1</td>
<td>BE</td>
<td>Bladder clear cell adenocarcinoma</td>
<td>Urinary incontinence, 4 year history of pelvic endometriosis</td>
<td>Pelvic US, TURBT</td>
</tr>
<tr>
<td>Yu et al., 2013</td>
<td>1</td>
<td>45</td>
<td>1</td>
<td>TE</td>
<td>Central-type lung cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lacroix-Triki et al., 2004</td>
<td>1</td>
<td>50</td>
<td>50</td>
<td>NE</td>
<td>Low-grade endometrial stroma of sciatic nerve</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Some reviews have addressed the use of hormone replacement therapy (HRT) in postmenopausal women with endometriosis, but postmenopause is not the focus of this study. Ovarian and gastrointestinal cancers. Therefore, the use of hormonal compounds could become a reason for concern. We refer to the WHO Medical Eligibility Criteria (MEC) for recommendations on the hormonal treatments to use in the case of women aged 40 years or older with or without cardiovascular risks or severe hypertension.

In patients with endometriosis, safety represents a very important issue because patients may need long periods of treatments even during advanced reproductive years. Progestins (norethisterone acetate or Dienogest) have been proven effective in reducing various types of pain including dysmenorrhea and dyspareunia and, belonging to MEC category 1, should be preferred in perimenopausal women (Table 1). As far as the progesterone-only pill is concerned, persistent bleeding is a common finding, not occurring with combined contraception. Vaginal bleeding in perimenopausal women requires further investigation in order to exclude all other gynecological pathologies that more commonly manifest above 40 years of age. Therefore, additional costs and invasive procedures, namely hysteroscopy, may be required, and could even be considered as additional side effects in the case of progesterone-only treatment. Low-dose oral norethisterone acetate is probably the best choice for rectovaginal lesions. COCs, belonging to MEC category 2, can be generally used cyclically or continuously in women with low risks and constitute an adequate first-line option for peritoneal and ovarian endometriosis. This hormonal therapy is also effective to reduce the risk of recurrences of these lesions, above all on endometrioma reformation after surgical excision. In patients with painful endometriosis close to menopause, considering the side effect of COCs, gonadotropin releasing hormone agonist [GnRH-a] should be cited, unsuitable for the long term but very effective in reducing pain in the short term.

As far as the risk for cancer is concerned, women who have used COC for prolonged periods for ovarian endometriomas should be informed that they are simultaneously protected from an increase in the risk of endometriosis-associated ovarian cancer. According to Modugno et al., the use of COCs for >10 years is associated with a 80% reduction in risk. After the early forties, however, unilateral oophorectomy plus bilateral salpingectomy could be the best risk-reducing approach, as this would imply not only prevention of endometrioid and clear cell tumors, but also of high-grade serous ones. The use of hormonal drugs increases the risk of developing cervical cancer, but this risk is counterbalanced by the compliance of women to the national screening programs for this disorder. Less clear data regard breast cancer but, again, screening and routine clinical examinations are able to decrease the potential minimal risk induced by the hormonal treatment.

Hormone replacement therapy in women with surgical-induced menopause for endometriosis

Some reviews have addressed the use of hormone replacement therapy (HRT) in postmenopausal women with endometriosis but postmenopause is not the focus of this study.
article. On the other hand, middle-aged women might receive surgical treatment leading to a surgical-induced menopause. Women should not be denied HRT treatment simply because of a history of endometriosis as there is a general consensus that the benefits of its use would far outweigh its risks, particularly in women with an early natural or surgical menopause. Moreover, there appears to be no reason to delay starting HRT after surgery. A full and frank discussion with the patient should be held about the risks and benefits of this treatment. The risk for malignant transformation of endometriotic tissue is increased in women with residual disease after surgery. Unopposed estrogen might carry the highest risk; it may be safer to give either continuous combined estrogen–progestogen therapies or tibolone as the risk of recurrence may be reduced.

**Methods**

Information for this review was identified by searches of Medline and PUBMED and references from relevant articles from inception until March 2018 using combinations of the MESH terms ‘endometriosis’ OR ‘endometriosis management’ OR ‘endometriosis medical treatment’ OR ‘endometriosis malignant transformation’ OR ‘endometriosis-associated cancer’ OR ‘endometriosis-associated tumor’ OR ‘endometriosis surgery’ with ‘perimenopause’ OR ‘middle-aged women’. The search was limited to peer-reviewed, full-text articles in the English language. Three authors (P.V., J.O., L.B.) reviewed the articles and discrepancies were resolved by consensus. The eligibility of the studies was firstly based on titles and abstracts. Full manuscripts were obtained for all selected papers and decision for final inclusion was made after detailed evaluation of the articles. Abstracts accepted in conferences were excluded from the review.

**Management of urinary tract endometriosis in middle-aged women**

**Bladder endometriosis**

Contradictory data are reported about the optimal treatment (medical or surgical) in bladder endometriosis in women older than 40 years of age. Westney et al. reported excellent results in 14 patients with bladder endometriosis treated with either low-dose COC or progestins: 92% of patients reported partial or complete resolution of symptoms with a median follow-up of 18.6 months. The mean age of this cohort of patients was 48.7 years, with 78.6% of patients being older than 40 years.

Others claimed that both the symptoms associated with bladder endometriosis and the lesion itself may respond suboptimally to medical therapies due to the desmoplastic reaction within the detrusor resulting from repetitive bleeding and consequent continuous local insult. Recurrence might be an issue in this context. Conversely, possible complications related to the surgery should not be underestimated in patients approaching menopause. Indeed, if endometriosis lies very close to the trigone, surgical excision can cause postoperative neurogenic bladder. Moreover, in about 10% of the women, vesicovaginal fistulas have been described. Importantly, since the lesions might be associated to other deep localizations, surgery tends to be performed in conjunction with other high-risk procedures such as bowel surgery.

Thus, according to the limited evidence, hormonal treatments (COCs and progestogens) may not cure but seem to be effective in temporarily suppressing bladder endometriosis in women with an impending menopause. In any case, patients should be informed that the disease may progress after medical treatment, so regular follow-up is advisable. For patients with contraindications to hormonal therapies or who refuse the medication but experience pain despite medical treatment, surgical excision of bladder endometriosis should be performed.

**Ureteral endometriosis**

Treatment of ureteral endometriosis is primarily surgical. The surgical treatment aims to relieve ureteral obstruction and avoid recurrence. It should be tailored, from ureterolysis to ureteroneocystostomy or ureteral resection with end-to-end anastomosis, depending on the extent of the ureteral infiltration, the location of the lesion, and the conditions of the ureter after ureterolysis. Moreover, hysterectomy with or without bilateral salpingo-oophorectomy may be considered in women with obstructive ureteral disease older than 40 years who have completed childbearing. Hysterectomy should be combined with the removal of any other endometriotic implants, especially deep lesions often associated with ureteral endometriosis. It should be underlined that with ovarian conservation, 27% of patients will need additional surgery for recurrent pelvic pain, whereas only 3% of patients undergoing hysterectomy and oophorectomy will require reoperation.

**Management of bowel endometriosis in middle-aged women**

**Benign symptomatic bowel endometriosis**

In women with known intestinal endometriosis, the perimenopausal years pose a challenge due to persistence of pain, reactivation, or malignant degeneration, even in women with prior surgery. Women previously operated for bowel endometriosis approaching menopause with no signs of recurrence and a good control of symptoms with medical therapy should continue hormonal therapy in use, if not contraindicated. Surgery, on the other side, is generally performed for obstructive lesions and for treatment of refractory pain. The patient should be aware that definitive surgery will not necessarily cure the disease, since cases of bowel endometriosis that occurred after surgical menopause are reported in the literature in about 14% of cases.
Bowel endometriosis presenting as acute bowel occlusion

Although rare, acute bowel obstruction is a serious complication of bowel endometriosis, more commonly found in women presenting with rectosigmoid involvement and requiring emergency surgery. Table 2 reports the cases of acute bowel occlusion presenting in perimenopausal women with endometriosis, most of them occurring without a previous diagnosis of the disease. The acute event has been preceded by bowel symptomatology such as constipation or diarrhea in some cases, not necessarily correlated to menses. Because malignant transformation cannot be excluded preoperatively and medical treatment may cause fibrosis, the definitive treatment is generally a surgical resection of the affected bowel segment, enabling the histopathological examination of the resection material.

Management of ovarian endometriosis in middle-aged women

Progestins and COCs showed great success in the treatment of symptoms related to ovarian endometrioma during reproductive age and they are considered as first-line treatment until 50 years of age. Surgery should be offered to symptomatic patients unresponsive to medical therapy independently of their age. The available evidence supports long-term medical therapy also after surgery to prevent recurrence of the disease and symptoms. However, in middle-aged women the risk of an occult malignancy in the endometriotic cyst represents a critical issue. Thus, the risks associated with surgery (complications, recurrences, surgical menopause) should be balanced with the risks associated with malignant transformation. Ovarian cystectomy represents the gold standard for the surgical treatment of an endometrioma, although in patients approaching menopause who have satisfied their pregnancy desire, bilateral salpingo-oophorectomy is a reasonable option to lower the risk of recurrences and ovarian cancer.

Management of rare endometriosis: thoracic endometriosis syndrome and endometriosis involving the nervous system

Catamenial pneumothorax is primarily treated by definitively managing the presenting feature (e.g. chest tube drainage of pneumothorax) followed by secondary prevention of recurrences (e.g. blebectomy, pleurodesis, repair of diaphragmatic fenestrations followed by hormonal suppression).

Consistent data on the management of thoracic endometriosis syndrome in the perimenopause period are lacking; five cases of thoracic endometriosis in women aged 40–50 years have been described. Four cases reported a right-sided pneumothorax (80%) that seems to be the most frequent side for location of thoracic endometriosis, while in one case (20%) pneumothorax has not been reported but thoracic endometriosis syndrome was associated with the presence of right-sided pleural effusion and adhesions on the pleural surface with hemorrhagic spots. The thoracic location of endometriosis was associated with an intestinal endometriosis in 20% of the cases, while in another case the patient presented also adenomyosis, ovarian cyst, and ascites. Clinically, chest pain during menstrual period was present in four cases (80%) and other respiratory symptoms, such as breathlessness, cough, and chest discomfort, have also been frequently reported in association (60%). The complete absence of thoracic clinical symptoms has been reported in two cases (40%). The management included medical treatment, mostly with GnRH-a and progestins (medroxyprogesterone acetate, cyproterone), and surgical treatment, represented by pleurodesis and/or hysterectomy and salpingo-oophorectomy. Thus, according to experience and data from observational studies, patients affected should be treated with hormonal therapy (COCs or progestins) if there are no serious side effects. However, if recurrence occurs during hormonal therapy or side effects are intolerable, bilateral salpingo-oophorectomy is indicated.

Endometriosis involving the nervous system, or ‘neuroendometriosis’, is an infrequent finding. Seventeen cases of neurologic endometriosis diagnosed in perimenopausal age have been reported in 14 studies. Somatic nerves were involved in 15 of the women and the central nervous system was involved in two. Clinical management included surgical treatment, mostly represented by neurolysis and/or hysterectomy and salpingo-oophorectomy, and/or treatment with GnRH-a.

Malignant transformation of endometriosis lesions in middle-aged women

Malignant transformation of endometriosis is estimated to occur in about 0.7–1.6% of women affected by endometriosis, with the ovary being the primary site in 79% while extraovarian sites account for about 20% of cases. Specific criteria are recognized for the malignant transformation of endometriosis.

Cases of malignant transformation of bladder endometriosis

There are only nine cases describing cancer from bladder endometriosis, with four cases being in perimenopause. The histological type was primarily clear cell carcinoma, while the endometrioid adenocarcinoma was the second most common. A univocal treatment approach is lacking and there are no shared guidelines for adjuvant medical treatment, consequently the commonly used chemotherapy for ovarian cancer has always been appointed. Based on the few available data, it is not possible to determine whether bladder tumors originating from malignant transformation of urinary endometriosis have a better prognosis than primitive bladder tumors, but a case of tumor due to recurrence of the specific disease has yet to be reported.
Cases of malignant transformation of bowel endometriosis

Slavin et al.\(^7,7\) described 23 cases of endometriosis-associated intestinal tumors, 10 of which were in perimenopausal age. All considered cases underwent surgical treatment with a subgroup following chemotherapy (three cases) or radiotherapy (two cases). The majority of patients survived with no evidence of disease whereas death occurred in four patients\(^7,7\). Kobayashi et al.\(^7,8\) reported the case of a 45-year-old woman previously diagnosed with endometriosis affected by an endometrioid adenocarcinoma of the rectosigmoid, and readily discussed all of the reported cases of endometriosis-derived intramural endometrioid adenocarcinomas (4 out of 14 cases in perimenopausal age). The median age of the cohort at diagnosis was 55 years (range 38–80 years). Twenty-two percent of the patients had been previously treated for endometriosis. Primary surgical treatment was considered the treatment of choice with complete resection of all disease and appropriate staging biopsies. Even if the use of adjuvant chemotherapy in advanced stage is controversial, platinum drugs and taxol were given in some cases. Most endometriosis-associated endometrioid carcinomas are low grade and limited to their site of origin, with a generally good prognosis\(^7,8\).

Concerning high-grade endometriosis-associated stromal sarcoma (ESS), Chen et al.\(^7,9\) described a tumor emerging in a 42-year-old woman with no history of endometriosis and reviewed another 10 cases reported in the literature, three of these in perimenopause. Optimal cytoreductive surgery with adjuvant radiotherapy was considered the optimal therapy for ESS, with better outcomes than surgery alone. High-grade ESS has a worse prognosis than low-grade ESS, with higher relapse rates, requiring a life-long follow-up\(^8,0\).

Cases of malignant transformation of ovarian endometriosis

The risk of ovarian cancer appears particularly elevated among subjects with a long-standing (>10 years) history of ovarian endometriosis, women with recurrent endometriomas, or in the case of de-novo endometrioma in women aged >45 years\(^6\). Other potential risk factors for malignancy include endometrioma sized over 9 cm or rapid growth of the cyst\(^8,1\).

The treatment plan for each patient should undoubtedly be individualized based on the patient’s symptoms, age, family history, and ultrasound appearance.

Guerriero et al.\(^8,2\) showed that sonographic characteristics of ovarian endometriomas vary with age. As age increases, multilocular cysts and cysts with papillations and other solid components become more common, while the ‘typical’ ground glass echogenicity of cyst fluid and tender mass on ultrasound scan become less common. Papillary projections and solid components have been demonstrated to increase the risk of malignancy, but these findings may also occur in benign endometriomas, especially in older women. Therefore, ultrasound diagnosis could be challenging in this age group because of the most frequent ‘atypical aspects’. However, malignant transformation exhibits characteristic features like the overall ovarian masses: the presence of a ‘vascularized solid component’ is usually highly accurate in discriminating between benign and malignant cysts\(^8,2\). When a malignancy is doubtful or suspected, surgery is considered as first-line treatment. Strict surveillance or surgery options should be discussed with perimenopausal women with small typical long-standing or recurrent endometriomas, especially when modifications of ultrasonographic cyst patterns occur.\(^6\)

If surgery is chosen in women not wishing conception, removal of the affected ovary/ovaries rather than cystectomy together with bilateral salpingectomy should be performed.

Cases of malignant transformation of thoracic and neurological endometriosis

A single case with malignant transformation of thoracic and neurological endometriosis in perimenopausal age has been described in the literature (Table 4)\(^8,1,8,3\).

Conclusions

This state-of-the-art review aims for the first time to assess the benefits and safety of the various therapies that can direct endometriosis treatment decisions for women approaching menopause. The menopause age for women with endometriosis is presently poorly defined but safety represents a critical issue for these women because they may need long periods of treatments even during advanced reproductive years. Progestins seem effective in suppressing, but not curing, bladder, bowel, and thoracic endometriosis in women with a good control of symptoms. Hysterectomy with bilateral salpingo-oophorectomy is currently the definitive therapy for women who have completed their reproductive arc and for those with failed medical therapy. For ovarian endometriosis, strict surveillance or surgery with removal of the affected gonads should be considered in cases of long-standing or recurrent endometriomas, especially in the presence of modifications of ultrasonographic cyst patterns. Although malignant transformation is rare, cases in endometriosis women approaching menopause have been described.

Acknowledgements

All of the authors of the Endometriosis Treatment Italian Club (ETIC Group) conceived the study and discussed the evidence. Paola Viganò, Jessica Ottolina, Ludovica Bartiromo, and Massimo Candiani contributed to the first draft of the article; all authors revised the article and approved the final version.

Conflict of interest No potential conflict of interest in relation to this topic was reported by the authors.

Source of funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
References

14. Matorras R, Elorriaga MA, Pijoan JM, Ramón O, Rodríguez-Escudero FJ. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril 2002;77:303–8


62. Floyd JR, Keeler ER, Euscher ED, McCutcheon IE. Cyclic sciatica from extrapelvic endometriosis affecting the sciatic nerve. *J Neurol Neurosurg Psychiatry* 2011;82:428–9


74. Miller EM, Sun Y, Richardson I, Frimer M. Vesical clear cell adenocarcinoma arising from endometriosis: a mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. *Gynecol Oncol Rep* 2016;18:8–10


